Expanding the Therapeutic Window in Oncology: Modern Strategies and Future Directions

Background: The enhancement of the therapeutic window (TW) in oncology remains a significant challenge, as the majority of anticancer treatments face difficulties in achieving optimal tumor control while minimizing adverse effects. Traditional chemotherapeutic agents, while demonstrating efficacy, are constrained by their limited TWs and the occurrence of systemic adverse effects. Objective: Recent advancements in precision medicine have revolutionized this paradigm by facilitating targeted tumor intervention via molecularly guided therapies, immuno-oncology strategies, and biomarker-driven patient classification. Novel approaches, including nanomedicine, antibody–drug conjugates, and prodrug formulations, improve therapeutic selectivity through the optimization of drug delivery, biodistribution, and release kinetics. Methodology: The concurrent advancements in radiotherapy, adaptive dosing methodologies, and toxicity assessment instruments have expanded the potential to enhance treatment intensity while preserving the integrity of normal tissues. In the future, the convergence of artificial intelligence (AI), multiomics profiling, and systems biology is anticipated to enhance therapeutic decision-making and expedite the creation of more personalized and adaptive interventions. Results: The efficacy of cancer treatments is substantially limited by notable shortcomings in research, despite progress in precision oncology. Tumor heterogeneity, the emergence of resistance mechanisms, and the absence of reliable biomarkers for anticipating treatment outcomes present significant impediments. The utilization of multiomics data and AI in clinical decision-making remains in its early stages, constrained by limitations in data validation and standardization. Furthermore, the translation of transdisciplinary concepts into accessible treatments is crucial, especially in environments with limited resources. Consequently, addressing these multifaceted issues is essential for improving the efficacy and safety of cancer treatments. Conclusion: This review integrates contemporary strategies and examines prospective pathways for expanding the TW, highlighting the intersection of technology, biology, and clinical innovation in the progression of cancer treatment.